Pathways to Early Diagnosis: Neurogenetic Biomarkers in Alzheimer's Disease.

• Autor(a) principal: Vasconcelos, José Lucas Moura
• Data de Publicação: 2024
• Outros Autores: Filho , Aney Martins Evangelista, Maldonado , Caio Mário do Couto, Ramos , Cacilda Soares de Moura, Maccare , Gabriella Gamoski, Gregory , Gilmara Gabrielli, Barreira, Giulia Beatriz Rodrigues, Moraes , Juliana Nogueira Leal de, Oliveira, Kahysa Magalhães de, Silveira, Laura Maria Câmara, Dutra , Luiza Brito, Zaias , Lucas de Lima, Rozza , Matheus Franzotti, Benigno, Nara Lis Freire, Nieto , Nydia Lorena Siqueira, Polycarpo, Rafaela Bollini, Carvalho , Shakespeare Viana, Dantas , Samara Oliveira, Fundación , Sarah Geia Yaktine, Sá , Thauana Santana de, Moreira, Thatiane Carvalho
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1324
• topic: doença de Alzheimer; Alzheimer's disease

This paper proposes a literature review on neurogenetic biomarkers in Alzheimer's disease (AD), highlighting their fundamental role in early diagnosis and understanding of the disease's pathogenesis. The analysis covers the identification of specific genetic variants, such as those in the TOMM40 gene, and polymorphisms identified through genome-wide association studies (GWAS). Additionally, the differential expression of genes associated with AD in early stages offers a unique opportunity for more effective therapeutic interventions. Despite advances, challenges such as external validation and genetic variability are crucial. The neurogenetic approach represents progress in understanding the genetic heterogeneity in AD, providing a foundation for future research. The abstract highlights the promising implications of neurogenetic biomarkers and emphasizes the importance of ethical and social awareness.